BIANCO, ANGELO RAFFAELE
 Distribuzione geografica
Continente #
NA - Nord America 1.533
EU - Europa 978
AS - Asia 691
SA - Sud America 36
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.268
Nazione #
US - Stati Uniti d'America 1.505
IT - Italia 352
SG - Singapore 332
CN - Cina 177
HK - Hong Kong 160
UA - Ucraina 159
NL - Olanda 93
FI - Finlandia 86
DE - Germania 85
RU - Federazione Russa 82
IE - Irlanda 38
BR - Brasile 32
FR - Francia 32
GB - Regno Unito 25
CA - Canada 24
CI - Costa d'Avorio 23
SE - Svezia 21
IN - India 14
EU - Europa 3
MA - Marocco 3
MX - Messico 3
AR - Argentina 2
NO - Norvegia 2
VN - Vietnam 2
AT - Austria 1
AZ - Azerbaigian 1
BO - Bolivia 1
CH - Svizzera 1
CR - Costa Rica 1
EC - Ecuador 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
LT - Lituania 1
TN - Tunisia 1
Totale 3.268
Città #
Singapore 226
Chandler 199
Jacksonville 166
Hong Kong 157
Woodbridge 110
Millbury 106
Santa Clara 93
Amsterdam 88
Princeton 76
Ashburn 60
Beijing 43
Wilmington 38
Nanjing 37
Napoli 32
Naples 28
Ottawa 19
Nanchang 18
Milan 16
Ann Arbor 15
Helsinki 13
Houston 13
Seattle 12
Tianjin 11
Changsha 10
Jiaxing 10
Rome 9
Boston 8
Hebei 8
Falkenstein 7
Norwalk 7
The Dalles 7
Kunming 6
Moscow 6
Rozzano 6
Shenyang 6
Pune 5
Redwood City 5
Boardman 4
Des Moines 4
Falls Church 4
Leawood 4
Menfi 4
Salerno 4
Toronto 4
Bologna 3
Casablanca 3
London 3
Mexico City 3
Mugnano Di Napoli 3
New York 3
Nuremberg 3
Salvador 3
San Mateo 3
Serravalle Scrivia 3
Villaricca 3
Washington 3
Avellino 2
Belo Horizonte 2
Castellammare Di Stabia 2
Castrolibero 2
Dublin 2
Florence 2
Genova 2
Hangzhou 2
Hanoi 2
Indiana 2
Kronberg 2
Lanzhou 2
Latina 2
Los Angeles 2
Mariano Comense 2
Ningbo 2
Nola 2
Piove Di Sacco 2
Poggiomarino 2
Pregnana Milanese 2
Rapolla 2
Scafati 2
Suri 2
São Paulo 2
Walnut 2
Zhengzhou 2
Abidjan 1
Alfenas 1
Andover 1
Ardabil 1
Armavir 1
Arzano 1
Atri 1
Aversa 1
Baku 1
Bangalore 1
Bari 1
Benevento 1
Berazategui 1
Birigui 1
Bishkek 1
Bozen 1
Brasília 1
Brescia 1
Totale 1.810
Nome #
null 223
Manuale di Oncologia Clinica 111
Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-a genes on in vitro transformation of human mammary epithelial cells. 72
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. 67
null 67
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 67
Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. 63
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 59
Epidermal growth factor (EGFR) and Transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells. 51
Phorbol-12-myristate-13-acetate (PMA) induces resistance of human melanoma cells to NK and LAK-mediated cytotoxicity. 50
Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the b1 integrin profile of cultured human tumor cells. 50
Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. 50
Studies of some immunological properties of thyroid iodoproteins 50
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies 50
Recombinant IFN-alfa 2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells. 49
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 49
Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway death is antagonized by epidermal growth factor. 48
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 47
Advanced and Locally unresectable gastric carcinoma: five years of survival with good quality of life. 47
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 46
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. 46
Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study. 45
Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. 45
CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia 45
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 44
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 43
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 43
ANTITUMOR ACTIVITY OF COMBINED BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND PROTEIN KINASE A 42
Overexpression of wild-type p53 ovverrides the mitogenic effect of the RIa subunit of protein kinase A in human breast cells. 42
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. 42
A predictive index of axillary nodal involvement in operable breast cancer. 42
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. 42
Core curriculum. Oncologia clinica 42
cERBB-2 OVEREXPRESSION DECREASED THE BENEFIT OF ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER WITHOUT AXILLARY LIMPHONODE METASTASES 40
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. 40
EGF activates an inducible survival response via the RAS -> Erk-1/2 pathway to counteract interferon-alfa-mediated apoptosis in epidermoid cancer cells. 40
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. 40
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 39
Carboplatin, epirubicin and VP-16 chemotherapy in the treatment of small cell lung cancer. 39
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. 39
Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. 38
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 38
Prognostic significance of multifocality in primary breast cancer. 38
Core curriculum. Oncologia clinica 38
Prognostic significance of circulating immune complexes in a long-term follow-up of breast cancer patients. 37
ZD1839 (Iressa): preclinical studies and pharmacology. 36
Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. 36
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 36
DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancer 36
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 36
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. 35
Breast cancer screening: characteristics and results of the Italian programmes in the Italian group for planning and evaluating breast cancer screening programmes (GISMa). 35
CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). 35
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 35
COOPERATIVE INHIBITION OF RENAL CANCER GROWTH BY ANTI-EGF-RECEPTOR ANTIBODY AND PROTEIN KINASE A ANTISENSE OLIGONUCLEOTIDE 34
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 34
Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer. 34
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 33
Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile? 33
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumour activity with EGFR inhibitors 33
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy. 32
THE RIa SUBUNIT OF PROTEIN KINASE (PKA) BINDS TO GRB2 AND ALLOWS PKA INTERACTION WITH THE ACTIVATED EGF-RECEPTOR 30
Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. 29
Tumori urologici 27
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 27
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 26
SYNERGISTIC INHIBITION OF HUMAN CANCER CELL GROWTH BY CYTOTOXIC DRUGS AND MIXED BACKBONE ANTISENSE OLIGONUCLEOTIDES TARGETING PROTEIN KINASE A 26
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. 25
DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospectine series of 515 primary breast cancer. 23
LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study). 22
The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. 22
Phase II study of mitomycin C, etopside and vindesine (MEV) in metastatic, stage IV, non small cell lung cancer. 22
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer. 22
First-line systemic therapy for metastatic breast cancer and management of pleural effusion. 21
The adjuvant treatment of ovarian cancer: result of the pilot study of a new combination chemotherapeutic regimen (DAC). 20
Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.). 20
HER-2/neu receptor in prostate cancer development and progression to androgen independence. 19
Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. 18
Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? 17
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials 16
A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients 12
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol. 12
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer 8
Totale 3.362
Categoria #
all - tutte 15.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.445


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020144 0 0 0 0 0 0 0 0 1 25 38 80
2020/2021352 15 30 44 36 42 47 37 4 42 4 44 7
2021/2022408 9 1 2 5 1 16 2 15 44 49 111 153
2022/2023522 81 47 22 18 57 50 9 43 71 94 25 5
2023/2024348 16 58 45 30 21 42 6 34 3 4 60 29
2024/2025867 113 180 5 9 75 82 224 149 30 0 0 0
Totale 3.362